Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child

2018 ◽  
Vol 44 (3) ◽  
pp. 322-324 ◽  
Author(s):  
P. Sahu ◽  
P. Aggarwal ◽  
S. Dayal ◽  
V. Kumar Jain
Keyword(s):  
Hidradenitis Suppurativa ◽  
Biologic Therapy ◽  
Prepubertal Child

scholarly journals Management of severe hidradenitis suppurativa with biologic therapy and wide excision

2019 ◽  
Vol 46 (3) ◽  
pp. 272-276 ◽  
Author(s):  
Shi Yu Derek Lim ◽  
Ee Cherk Cheong ◽  
Hazel H. Oon
Keyword(s):  
Hidradenitis Suppurativa ◽  
Biologic Therapy ◽  
Wide Excision

scholarly journals Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy

2017 ◽  
Vol 57 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Victoria K. Shanmugam ◽  
Shaunak Mulani ◽  
Sean McNish ◽  
Sarah Harris ◽  
Teresa Buescher ◽  
...  
Keyword(s):  
Observational Study ◽  
Hidradenitis Suppurativa ◽  
Surgical Intervention ◽  
Biologic Therapy ◽  
Longitudinal Observational Study

Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa

2018 ◽  
Vol 37 (3) ◽  
pp. 182-189 ◽  
Author(s):  
Martina L Porter ◽  
Nicole M Golbari ◽  
Stephen J Lockwood ◽  
Alexa B Kimball
Keyword(s):  
Hidradenitis Suppurativa ◽  
Biologic Therapy

An assessment of current practices in the treatment of hidradenitis suppurativa: the rise of biologic therapy

2020 ◽  
pp. 1-4
Author(s):  
Suraj Muddasani ◽  
Kelsey S. Flood ◽  
Alan B. Fleischer
Keyword(s):  
Hidradenitis Suppurativa ◽  
Biologic Therapy ◽  
Current Practices

scholarly journals Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa

2016 ◽  
Vol 77 (2) ◽  
pp. 217-222 ◽  
Author(s):  
Michael V. DeFazio ◽  
James M. Economides ◽  
Kathryn S. King ◽  
Kevin D. Han ◽  
Victoria K. Shanmugam ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Biologic Therapy ◽  
Radical Resection

scholarly journals Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study

2020 ◽  
Vol 100 (16) ◽  
pp. adv00257
Author(s):  
L Salvador-Rodriguez ◽  
C Cuenca-Barrales ◽  
S Arias-Santiago ◽  
A Molina-Leyva
Keyword(s):  
Cohort Study ◽  
Surgical Management ◽  
Hidradenitis Suppurativa ◽  
Biologic Therapy

scholarly journals Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review

2021 ◽  
pp. 120347542110497
Author(s):  
Muskaan Sachdeva ◽  
Patrick Kim ◽  
Asfandyar Mufti ◽  
Khalad Maliyar ◽  
Cathryn Sibbald ◽  
...  
Keyword(s):  
Systematic Review ◽  
Complete Resolution ◽  
Hidradenitis Suppurativa ◽  
Large Scale ◽  
Pediatric Patients ◽  
Biologic Therapy ◽  
Pediatric Population ◽  
Safety Data ◽  
Tnf Alpha ◽  
The Mean

Background: There is currently at least 1 biologic (adalimumab) approved in North America for treatment of Hidradenitis Suppurativa in the pediatric population. However, no reviews or clinical trials have specifically analyzed the effectiveness and safety data of biologic use in this population. The objective of this systematic review is to identify and summarize the outcomes of biologic therapy in pediatric patients with HS. Methods: MEDLINE and EMBASE databases were used to conduct the search on Sept 18, 2020. Results: The 15 included studies consisted of 26 patients, with the mean age of 15 ± 2.3 years. Females accounted for 53.8% ( n = 14/26) of cases. The mean duration of HS prior to biologic initiation was 3.5 ± 2.9 years, with the majority having Hurley Stage II. The 26 patients received 34 biologics in total: 85.3% treated with TNF alpha inhibitors (adalimumab n = 17, infliximab n = 10, etanercept n = 1, unspecified n = 1), 5.9% with IL-12/23 inhibitors (ustekinumab n = 2), 5.9% with IL-1 inhibitors (i.e., anakinra n = 2) and 2.9% received IL-23 inhibitors (i.e., guselkumab n = 1) biologics. Of the 26 patients, 23.1% ( n = 6/26) experienced complete resolution (CR), 73.1% ( n = 19/26) experienced partial resolution (PR), and 3.8% ( n = 1/26) had no resolution outcomes reported. The time to resolution of HS lesions after biologic initiation ranged from 10 days to 11.5 months (mean: 5.1 months). No adverse events were reported in the studies. Conclusion: Although anti-TNF alpha were the most common biologics used for HS in pediatric cases, large-scale trials specific to pediatric patients with HS are needed to confirm these findings.

scholarly journals Biologic Therapy for Hidradenitis Suppurativa Plus Conglobate Acne Associated with SAPHO Syndrome: A Case Report

2020 ◽  
Vol 100 (18) ◽  
pp. adv00311 ◽  
Author(s):  
K Briede ◽  
S Valiukeviciene ◽  
V Kucinskiene ◽  
H Gollnick
Keyword(s):  
Case Report ◽  
Hidradenitis Suppurativa ◽  
Biologic Therapy ◽  
Sapho Syndrome
Sign in / Sign up

Export Citation Format

Share Document